Dan (for Francis Brisebois)'s questions to Mediwound Ltd (MDWD) leadership • Q3 2024
Question
Dan, on behalf of Francis Brisebois at Oppenheimer, asked about the success criteria for the Phase II head-to-head study of EscharEx versus collagenase and the expected impact of the recent WHO inclusion on NexoBrid stockpiling timelines.
Answer
Ofer Gonen (Executive) explained that the head-to-head study is designed similarly to a previous successful trial and aims to generate credible, predefined data for pricing discussions by showing a similar clinical impact. Regarding the WHO designation, he noted it's a significant achievement and a prerequisite for discussions with European authorities (EU HERA) but stated that significant stockpiling agreements are not expected until 2026, once current manufacturing capacity constraints are resolved.